Stay updated with breaking news from Sight Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sustained efficacy three years after injection: statistically significant visual acuity improvement from nadir Continuous benefits in bilaterally treated patients with +17 to +20 ETDRS letters
PPQ campaign to start early May 2023 (previously end of March) with results expected in Q3 2023 EMA CHMP opinion now expected in Q1 2024 (previously September 2023) Regulatory News: GenSight
Leber Hereditary Optic Neuropathy (LHON) is a rare disease predominantly affecting people aged 15 to 35 year that causes irreversible and severe vision loss, resulting in blindness Patients
Proceeds intended to support the development of GenSight Biologics' product portfolio, including the preparation of the LUMEVOQ European launch expected by the end of 2023 Regulatory News: GenSight
04.01.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system ...